Boston, MA 09/30/2014 (wallstreetpr) – According to reports, Takeda Pharmaceutical Co Ltd (ADR)(OTCMKTS:TKPYY) and Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have decided to launch a direct to consumer advertisement campaign for AMITIZA. Both the companies will run this campaign in a few selected markets of US.
Insights of the campaigning:
As per the information, the campaigning will consists of a sixty seconds television spot that will be aired on different platforms and programs such as Good Morning America, the Oprah Winfrey Network and Headline News Network. Apart from advertising on digital media, both the companies have also decided to run a campaign on print media as well. As per the reports, a print advertisement will run in all the outlets of the brand including USA Weekend, Woman’s Day and Good Housekeeping. Management executives of both the companies are very delighted to make an announcement about this campaign. Recently Peter Greenleaf, Chief Executive Officer of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), told reporters that the main objective of the company had been developing brand AMITIZA for last some time. He made a note of the same objective during the earning call for SCMP’s second quarter.
Greenleaf also stated that the company was trying its best to educate patients about AMITIZA. There is a dangerous condition called CIC, many of the customers remain unaware about it, which can be very harmful to their health. AMITIZA can be a one stop solution for CIC and can cure it in minimum time without hurting patients’ pocket. AMITIZA is very new in the US market. It has very good potential, and that’s the main reason Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Takeda Pharmaceutical Co Ltd (ADR)(OTCMKTS:TKPYY) are trying their best to educate local people about this drug in the best way possible. The campaign is one of the steps that both the companies have planned to market AMITIZA. In coming months, customers can see a lot more such efforts taking place in other parts of the country as well.
